/주식/NUVL
NUVL

NUVL

USD

Nuvalent Inc. Class A Common Stock

$92.690-1.560 (-1.655%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$94.250

고가

$95.225

저가

$92.075

거래량

0.28M

기업 기본 정보

시가총액

6.7B

산업

생명공학

국가

United States

거래 통계

평균 거래량

0.46M

거래소

NMS

통화

USD

52주 범위

저가 $55.535현재가 $92.690고가 $104.9

관련 뉴스

PR Newswire

Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

더 보기
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Analyst Upgrades

UBS Maintains Buy on Nuvalent, Raises Price Target to $132

UBS analyst David Dai maintains Nuvalent with a Buy and raises the price target from $114 to $132.

더 보기
UBS Maintains Buy on Nuvalent, Raises Price Target to $132
PR Newswire

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

더 보기
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128

Piper Sandler analyst Kelsey Goodwin maintains Nuvalent with a Overweight and raises the price target from $112 to $128.

더 보기
Piper Sandler Maintains Overweight on Nuvalent, Raises Price Target to $128